Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Does the MarketBeat Community prefer CORT or RPRX?

Corcept Therapeutics received 221 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.26% of users gave Corcept Therapeutics an outperform vote while only 67.98% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Corcept Therapeutics	Outperform Votes 548 71.26%	Underperform Votes 221 28.74%
Royalty Pharma	Outperform Votes 327 67.98%	Underperform Votes 154 32.02%

Do institutionals and insiders believe in CORT or RPRX?

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is CORT or RPRX more profitable?

Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	22.35%	24.54%	20.24%
Royalty Pharma	37.94%	24.40%	14.01%

Do analysts rate CORT or RPRX?

Corcept Therapeutics currently has a consensus target price of $138.25, indicating a potential upside of 81.38%. Royalty Pharma has a consensus target price of $42.50, indicating a potential upside of 28.44%. Given Corcept Therapeutics' higher probable upside, equities research analysts clearly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media favor CORT or RPRX?

In the previous week, Royalty Pharma had 2 more articles in the media than Corcept Therapeutics. MarketBeat recorded 17 mentions for Royalty Pharma and 15 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.09 beat Royalty Pharma's score of 1.04 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, CORT or RPRX?

Corcept Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Which has stronger earnings & valuation, CORT or RPRX?

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$685.45M	11.79	$106.14M	$1.16	65.71
Royalty Pharma	$2.26B	8.43	$858.98M	$1.85	17.89

Summary

Corcept Therapeutics beats Royalty Pharma on 11 of the 18 factors compared between the two stocks.